What is HC Wainwright’s Estimate for Savara Q1 Earnings?

Savara Inc. (NASDAQ:SVRA) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Savara in a research note issued to investors on Monday, March 16th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.09) EPS, FY2029 earnings at $0.41 EPS and FY2030 earnings at $0.72 EPS.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

A number of other research analysts have also weighed in on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Guggenheim reissued a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Saturday. Wells Fargo & Company lifted their price target on Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, December 18th. Finally, UBS Group set a $10.00 price target on shares of Savara in a research note on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Savara Stock Performance

Shares of SVRA opened at $5.15 on Tuesday. The company has a quick ratio of 7.65, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.05 billion, a P/E ratio of -9.72 and a beta of 0.31. The business’s 50 day moving average price is $5.65 and its 200-day moving average price is $4.99. Savara has a 52 week low of $1.89 and a 52 week high of $7.01.

Institutional Trading of Savara

A number of hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. purchased a new position in Savara in the second quarter valued at $30,000. BNP Paribas Financial Markets raised its stake in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new stake in Savara in the 2nd quarter valued at $33,000. Russell Investments Group Ltd. raised its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the period. Finally, Quadrature Capital Ltd purchased a new position in Savara during the second quarter valued at $42,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.